Correction: Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
Renshi Kawakatsu, Kenjiro Tadagaki, Kenta Yamasaki, Tatsushi Yoshida
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 5Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAcute Myeloid Leukemia Research
Correction to: Scientific Reports 10.1038/s41598-024-55286-0, published online 29 February 2024
The original version of the Article contained an error in Fig. 5, where in Fig. 5C “Control” image was a duplication of the “NaB 1 mM” image.
The original Fig. 5 and accompanying legend appear below.Fig. 5. Caspase activation was induced by the combination of venetoclax and NaB. KG-1 was treated with venetoclax alone or the combination with venetoclax and NaB for 48 h. (A) Western blotting of PARP. Cell lysates were extracted and western blotting was performed. Upper panel; PARP, Lower panel; actin. Molecular weight marker was shown at the left side. The PARP-cleaved form generated by caspase activation was indicated by an arrow. Original blots are presented in Supplemental Fig. 3. Quantification of band intensity was shown in Supplemental Fig. 4. (B) Trypan blue dye exclusion assay to examine the rate of live or dead cells. (C) Cell morphologies were observed using a microscope. (D,E) Cell cycle analyses of cells stained with PI using a flow cytometry. A bar graph with triplicate data (D) and representative histograms (E) were shown. The data was n = 3 ± S.D.. Vene; venetoclax.
The original Article has been corrected.